A pandemic influenza vaccine in India: From strain to sale within 12 months

Vaccine

Volumn 29, Issue SUPPL. 1, 2011, Pages

  Dhere, Rajeev ^a   Yeolekar, Leena ^a   Kulkarni, Prasad ^a   Menon, Ravi ^a   Vaidya, Vivek ^a   Ganguly, Milan ^a   Tyagi, Parikshit ^a   Barde, Prajakt ^a   Jadhav, Suresh ^a  

^a Serum Institute of India Ltd   (India)

Author keywords

Developing countries; H1N1; Influenza vaccine; LAIV; Pandemic; Production

Indexed keywords

ENZAVAC; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE ATTENUATED INFLUENZA VACCINE; LIVE VACCINE; NASOVAC; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; DEVELOPING COUNTRY; DRUG MARKETING; HUMAN; IMMUNITY; IMMUNIZATION; INDIA; INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MEDICAL SOCIETY; NONHUMAN; PANDEMIC INFLUENZA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; UNITED NATIONS; VIRUS STRAIN; WORLD HEALTH ORGANIZATION;

HUMANS; INDIA; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; TECHNOLOGY, PHARMACEUTICAL; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 79959203842     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.119     Document Type: Article

References (8)

1. Meeting with international partners on influenza vaccine technology transfer to developing country vaccine manufacturers, 29-30 October 2007. World Health Organization, WHO/IVB/08.09.
2. Jadhav S., Dhere R., Yeolekar L., Gautam M. Influenza vaccine production capacity building in developing countries: example of the serum institute of India. Procedia Vaccinol 2010, 2:166-171.
3. Rudenko L.G., Lonskaya N.I., Klimov A.I., Vasilieva R.I., Ramirez A. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds. Bull World Health Organ 1996, 74(1):77-84.
4. Powers D.C., Sears S.D., Murphy B.R., Thumar B., Clements M.L. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 1989, 27(12):2666-2671.
5. Karron R.A., Callahan K., Luke C., Thumar B., McAuliffe J., Schappell E., et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009, 199(March (5)):711-716.
6. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(25):2414-2423.
7. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
8. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Dawson G., Hu W., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(25):2405-2413.